Thiazolidinediones (TZDs), such as troglitazone, rosiglitazone, and pioglitazone, which act as PPARγ agonists, are employed to enhance the peripheral insulin sensitivity in individuals with diabetes and prediabetes. Here, INS is linked to prediabetes syndrome.